MannKind and Pfizer (New York) agreed that the former company will help patients who need inhaled insulin switch from Pfizer's "Exubera" medicine to MannKind's "Technosphere Insulin" drug. Valencia, ...
After burning $2.8 billion, Pfizer is throwing yet more money on the inhaled insulin bonfire. The company's announcement that it has a deal to switch former Exubera patients to MannKind's TechnoSphere ...
A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 diabetes who want ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results